| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/30/2014 | WO2014017999A1 Method for producing an agent for the treatment of tuberculosis |
| 01/30/2014 | WO2014017987A1 Method of promoting wound healing |
| 01/30/2014 | WO2014017936A2 Urea compounds and their use as enzyme inhibitors |
| 01/30/2014 | WO2014017928A1 Organic compounds |
| 01/30/2014 | WO2014017915A2 Urea and guanidinium derivatives of iminosugars |
| 01/30/2014 | WO2014017900A2 Novel bioactive compound obtained from oil palm base materials |
| 01/30/2014 | WO2014017897A1 New differential-release pharmaceutical composition containing three active principles |
| 01/30/2014 | WO2014017833A1 Composite formulation for oral administration comprising metformin and rosuvastatin |
| 01/30/2014 | WO2014017803A1 Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same |
| 01/30/2014 | WO2014017802A1 Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same |
| 01/30/2014 | WO2014017797A1 Novel method for preparing 1-oxacephalosporin derivative |
| 01/30/2014 | WO2014017787A1 Pharmaceutical composition having antidiabetic and antiobesity activities |
| 01/30/2014 | WO2014017741A1 Pharmaceutical composition containing prunetin as active ingredient for preventing or treating obesity or metabolic diseases |
| 01/30/2014 | WO2014017659A1 Agent for treating or controlling recurrence of acute myelogenous leukemia |
| 01/30/2014 | WO2014017643A1 Difluoromethylene compound |
| 01/30/2014 | WO2014017595A1 Patch |
| 01/30/2014 | WO2014017594A1 Adhesive patch |
| 01/30/2014 | WO2014017593A1 Adhesive patch and production method therefor |
| 01/30/2014 | WO2014017573A1 Composition for agent for external use |
| 01/30/2014 | WO2014017569A1 Pharmaceutical product for lowering blood ldl |
| 01/30/2014 | WO2014017515A1 4-[5-(pyridine-4-yl)-1h-1,2,4-triazole-3-yl]pyridine-2-carbonitrile crystalline polymorph and production method therefor |
| 01/30/2014 | WO2014017507A1 Solid pharmaceutical preparation |
| 01/30/2014 | WO2014017462A1 Pharmaceutical composition for inhibiting abnormal spine formation |
| 01/30/2014 | WO2014017451A1 Polysaccharide, composition containing polysaccharide, and immunostimulating agent |
| 01/30/2014 | WO2014017411A1 External preparation for treating trichophytosis unguium |
| 01/30/2014 | WO2014017342A1 Indole derivative or pharmacologically acceptable salt thereof |
| 01/30/2014 | WO2014017319A1 Filaggrin production promoter, therapeutic agent for diseases associated with reduction in production of filaggrin, and method for screening for said therapeutic agent |
| 01/30/2014 | WO2014017243A1 Sleep quality improving agent |
| 01/30/2014 | WO2014017145A1 Composition |
| 01/30/2014 | WO2014017093A1 Benzene ring-fused, nitrogen-containing 5-membered heterocyclic compound or pharmacologically acceptable salt thereof |
| 01/30/2014 | WO2014017087A1 Pyrazolopyridine derivative or pharmacologically acceptable salt thereof |
| 01/30/2014 | WO2014017046A1 Prophylactic and/or therapeutic agent for radiation damage |
| 01/30/2014 | WO2014016917A1 Acidic liquid nutrient |
| 01/30/2014 | WO2014016850A1 Stable pharmaceutical composition of fluindione |
| 01/30/2014 | WO2014016849A2 Novel triazine compounds |
| 01/30/2014 | WO2014016848A2 Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof |
| 01/30/2014 | WO2014016830A1 Process and intermediates for the preparation of abiraterone acetate |
| 01/30/2014 | WO2014016789A1 Pyrazolo[3,4-d]pyrimidin-4(5h)-one derivatives as pde9 inhibitors |
| 01/30/2014 | WO2014016766A1 Guanidine derivatives as trpc modulators |
| 01/30/2014 | WO2014016653A1 Pharmaceutical composition comprising diamorphine for intranasal administration |
| 01/30/2014 | WO2014016647A1 PHARMACEUTICAL COMPOSITION OF MILK FAT GLOBULES (MFGs) ZINC FREE |
| 01/30/2014 | WO2014016627A1 Vitamin and mineral preparations for gravidae for use in trimesters of pregnancy |
| 01/30/2014 | WO2014016585A1 Use of s-pindolol for treating cachexia and sarcopenia |
| 01/30/2014 | WO2014016548A2 Pharmaceutical composition |
| 01/30/2014 | WO2014016434A1 Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| 01/30/2014 | WO2014016433A1 Derivatives of azaindazole or diazaindazole type for treating pain |
| 01/30/2014 | WO2014016430A1 Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
| 01/30/2014 | WO2014016428A1 Opioid formulations |
| 01/30/2014 | WO2014016409A1 Uses of compositions containing a roasted extract and xanthohumol |
| 01/30/2014 | WO2014016407A1 Pharmaceutical or cosmetic composition for treating alopecia |
| 01/30/2014 | WO2014016396A1 Oral dosage forms for modified release comprising ruxolitinib |
| 01/30/2014 | WO2014016394A1 Misprostol composition |
| 01/30/2014 | WO2014016390A1 Misoprostol formulation |
| 01/30/2014 | WO2014016381A1 CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß- D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
| 01/30/2014 | WO2014016371A1 Micronized aleglitazar |
| 01/30/2014 | WO2014016370A1 Amorphous aleglitazar |
| 01/30/2014 | WO2014016369A1 Pharmaceutical formulation comprising aleglitazar and complexing agent |
| 01/30/2014 | WO2014016361A1 Multimeric mannosides, a process for preparing the same and their uses as a drug |
| 01/30/2014 | WO2014016358A1 Inhibition of hiv-1 infection by inhibition of binding of cpsf to viral capsid |
| 01/30/2014 | WO2014016317A1 Synthesis of diverse glycosylphosphatidylinositol glycans from toxoplasma gondii and their application as vaccines and diagnostics |
| 01/30/2014 | WO2014016314A1 Fused quinonic compounds |
| 01/30/2014 | WO2014016267A1 Benzisoxazole modulators of neurogenesis |
| 01/30/2014 | WO2014016266A1 Kudzu and phytosterols for use in the treatment of metabolic disorders |
| 01/30/2014 | WO2014016252A1 New treatment of fish with a nanosus pens ion of lufenuron or hexaflumuron |
| 01/30/2014 | WO2014016238A1 Compositions for oral administration having a beneficial effect on tendinopathies and ligament injuries |
| 01/30/2014 | WO2014016233A1 Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity |
| 01/30/2014 | WO2014016191A1 N-cyclopropyl-n-piperidinyl-amide derivatives and their use as gpr119 modulators |
| 01/30/2014 | WO2014016003A1 Use of biotin for the treatment of multiple sclerosis |
| 01/30/2014 | WO2014015993A1 Bicyclic aza-amides for treatment of psychiatric disorders |
| 01/30/2014 | WO2014015905A1 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors |
| 01/30/2014 | WO2014015830A1 Novel heteroaryl and heterocycle compounds, composition and methods thereof |
| 01/30/2014 | WO2014015760A1 Crystal form of cabazitaxel and preparation method thereof |
| 01/30/2014 | WO2014015754A1 Broussonetine compound, preparation method therefor, and application thereof |
| 01/30/2014 | WO2014015675A1 Novel heteroaryl and heterocycle compounds, compositions and methods |
| 01/30/2014 | WO2014015673A1 4-position substituted pyrazolopyrimidine derivative, and use thereof in drug preparation |
| 01/30/2014 | WO2014015672A1 Compound preparation of lercanidipine and atorvastatin |
| 01/30/2014 | WO2014015523A1 Novel heteroaryl and heterocycle compounds, compositions and methods |
| 01/30/2014 | WO2014015495A1 Inhibitors of the renal outer medullary potassium channel |
| 01/30/2014 | WO2014015467A1 Composition comprising phytosterols and kudzu and its use in the treatment, alleviation or prevention of metabolic disorders |
| 01/30/2014 | WO2014015462A1 Hawthorn and phytosterols and their effect on metabolic disorders |
| 01/30/2014 | WO2014015436A1 Apparatus and method of controlling the rate of nicotine delivery |
| 01/30/2014 | WO2014015422A1 Cellulose-based nanoparticles for drug delivery |
| 01/30/2014 | WO2014015416A1 Improvement of sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy |
| 01/30/2014 | WO2013188465A3 Treating drug addiction and preventing drug relapse |
| 01/30/2014 | WO2013185048A3 Heterocyclic guanidine f1f0-atpase inhibitors |
| 01/30/2014 | WO2013183062A3 Palatable formulations of ibuprofen |
| 01/30/2014 | WO2013181296A3 Compositions and methods for managing weight |
| 01/30/2014 | WO2013181202A3 Chromane compounds |
| 01/30/2014 | WO2013181174A3 Solid dosage formulations of an orexin receptor antagonist |
| 01/30/2014 | WO2013175395A3 Improved process for preparation of saxagliptin and its salts |
| 01/30/2014 | WO2013175377A3 Compositions and methods for treatment of mucositis |
| 01/30/2014 | WO2013175357A3 Compositions and methods for treatment of inflammatory bowel disease |
| 01/30/2014 | WO2013175347A3 Compositions and methods for treatment of respiratory disorders |
| 01/30/2014 | WO2013175344A3 Compositions and methods for treatment of peridontitis and rheumatoid arthritis |
| 01/30/2014 | WO2013173096A3 Conjugates of huperzine and analogs thereof |
| 01/30/2014 | WO2013168179A3 Controlled release pharmaceutical formulations of antiviral agents |
| 01/30/2014 | WO2013166396A3 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| 01/30/2014 | WO2013153349A3 Pharmaceutical composition comprising arformoterol and fluticasone furoate |
| 01/30/2014 | WO2013006734A8 Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity |
| 01/30/2014 | WO2012170889A8 Cleavable lipids |